rs121918208
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PM2PP3_ModeratePP5_Very_Strong
The NM_018122.5(DARS2):c.455G>T(p.Cys152Phe) variant causes a missense change. The variant allele was found at a frequency of 0.000107 in 1,613,926 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: 𝑓 0.00011 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00011 ( 0 hom. )
Consequence
DARS2
NM_018122.5 missense
NM_018122.5 missense
Scores
8
9
2
Clinical Significance
Conservation
PhyloP100: 6.17
Genes affected
DARS2 (HGNC:25538): (aspartyl-tRNA synthetase 2, mitochondrial) The protein encoded by this gene belongs to the class-II aminoacyl-tRNA synthetase family. It is a mitochondrial enzyme that specifically aminoacylates aspartyl-tRNA. Mutations in this gene are associated with leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL). [provided by RefSeq, Nov 2009]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.844
PP5
Variant 1-173831593-G-T is Pathogenic according to our data. Variant chr1-173831593-G-T is described in ClinVar as [Pathogenic]. Clinvar id is 1061.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr1-173831593-G-T is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
DARS2 | NM_018122.5 | c.455G>T | p.Cys152Phe | missense_variant | 5/17 | ENST00000649689.2 | NP_060592.2 | |
DARS2 | NM_001365212.1 | c.455G>T | p.Cys152Phe | missense_variant | 5/16 | NP_001352141.1 | ||
DARS2 | NM_001365213.2 | c.455G>T | p.Cys152Phe | missense_variant | 5/14 | NP_001352142.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
DARS2 | ENST00000649689.2 | c.455G>T | p.Cys152Phe | missense_variant | 5/17 | NM_018122.5 | ENSP00000497569 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000105 AC: 16AN: 152208Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
16
AN:
152208
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000111 AC: 28AN: 251326Hom.: 0 AF XY: 0.0000957 AC XY: 13AN XY: 135876
GnomAD3 exomes
AF:
AC:
28
AN:
251326
Hom.:
AF XY:
AC XY:
13
AN XY:
135876
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000107 AC: 157AN: 1461718Hom.: 0 Cov.: 31 AF XY: 0.000109 AC XY: 79AN XY: 727172
GnomAD4 exome
AF:
AC:
157
AN:
1461718
Hom.:
Cov.:
31
AF XY:
AC XY:
79
AN XY:
727172
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000105 AC: 16AN: 152208Hom.: 0 Cov.: 32 AF XY: 0.0000403 AC XY: 3AN XY: 74352
GnomAD4 genome
AF:
AC:
16
AN:
152208
Hom.:
Cov.:
32
AF XY:
AC XY:
3
AN XY:
74352
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
2
ExAC
AF:
AC:
9
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:9Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:4
Pathogenic, no assertion criteria provided | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Dec 06, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Feb 01, 2019 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 25, 2024 | This sequence change replaces cysteine, which is neutral and slightly polar, with phenylalanine, which is neutral and non-polar, at codon 152 of the DARS2 protein (p.Cys152Phe). This variant is present in population databases (rs121918208, gnomAD 0.03%). This missense change has been observed in individuals with leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (PMID: 17384640, 24566671). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 1061). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on DARS2 protein function. Experimental studies have shown that this missense change affects DARS2 function (PMID: 23216004). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Oct 07, 2024 | Published functional studies demonstrate a damaging effect with reduced protein expression and dimerization (PMID: 23216004); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 17384640, 29147736, 34426522, 31589614, 33686843, 31980526, 30325133, 24566671, 37563224, 23216004, 38790244, 38125072) - |
Leukoencephalopathy with brain stem and spinal cord involvement-high lactate syndrome Pathogenic:3Other:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jun 03, 2022 | Variant summary: DARS2 c.455G>T (p.Cys152Phe) results in a non-conservative amino acid change located in the dimerization interface (van Berge_2013) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00011 in 251326 control chromosomes. This frequency does not allow conclusions about variant significance. c.455G>T has been reported in the literature in multiple individuals affected with Leukoencephalopathy With Brain Stem And Spinal Cord Involvement-High Lactate Syndrome (example, Isohanni_2010, Steenweg_2012, van Berge_2014). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in reduced protein levels, decreased stability (approximately 50% of WT), decreased dimerization to WT and/or to the same or another mutation (approximately 30% of WT). Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Apr 01, 2007 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Apr 11, 2023 | - - |
not provided, no classification provided | literature only | GeneReviews | - | Several individuals share haplotypes involving five or six microsatellite markers on chromosome 1p25. The pathogenic variants 492+2T>C and 455G>T are correlated with two of these haplotypes and are often seen in affected individuals of northeastern European origin. - |
DARS2-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jan 18, 2024 | The DARS2 c.455G>T variant is predicted to result in the amino acid substitution p.Cys152Phe. This variant has been reported in individuals with autosomal recessive leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation (LBSL) (Scheper et al. 2007. PubMed ID: 17384640; van Berge et al. 2014. PubMed ID: 24566671, supplementary table 3). A functional study shows that this variant leads to reduced levels of the encoded protein (mitochondrial aspartyl-tRNA synthetase and dimerization) (van Berge et al. 2013. PubMed ID: 23216004). This variant is reported in 0.029% of alleles in individuals of European (Non-Finnish) descent in gnomAD. This variant is interpreted as pathogenic. - |
See cases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University Hospital Muenster | May 16, 2022 | ACMG categories: PS3,PM2,PP1,PP3,PP5 - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Uncertain
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Benign
T;.;.;.;T;.;.
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
.;D;D;D;D;D;D
M_CAP
Uncertain
D
MetaRNN
Pathogenic
D;D;D;D;D;D;D
MetaSVM
Uncertain
D
MutationAssessor
Uncertain
M;.;.;.;M;.;.
MutationTaster
Benign
A;A
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
D;.;.;.;.;.;.
REVEL
Pathogenic
Sift
Uncertain
D;.;.;.;.;.;.
Sift4G
Uncertain
D;.;.;.;.;.;.
Polyphen
P;.;.;.;P;.;.
Vest4
MVP
MPC
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at